GlassScriptPhysician profile
Brian R Tevlin
NPI 1689969503
$4,240.44
in general payments reported to CMS, 2019-2025
23 companies · $2,361 in 2025
The $2,361 reported for 2025 was more than what 97% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $278 · 2024: $1,602 · 2025: $2,361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,226 · Education: $14.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,225.84 |
| Education | $14.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $880.63 | 2023-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $600.89 | 2023-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $550.11 | 2023-2025 | Tremfya, Stelara |
| Qol Medical, LLC | $354.31 | 2024-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $342.37 | 2023-2025 | Dupixent |
| Madrigal Pharmaceuticals | $316.08 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $197.87 | 2024-2025 | |
| Ardelyx, INC. | $155.66 | 2024-2025 | Ibsrela |
| Organon LLC | $139.10 | 2024-2025 | Hadlima, Renflexis |
| Ipsen Biopharmaceuticals, INC | $114.00 | 2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $90.16 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $81.16 | 2024-2025 | Vowst |
| Ferring Pharmaceuticals INC. | $79.61 | 2023-2025 | Rebyota |
| Lilly USA, LLC | $58.48 | 2024-2025 | Omvoh, Zepbound |
| Neuraxis, INC. | $54.32 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $48.59 | 2023-2024 | |
| Celltrion USA INC. | $33.48 | 2024-2025 | Vegzelma, Zymfentra |
| Braintree Laboratories, INC. | $32.46 | 2024-2025 | Suflave, Sutab |
| Abbvie INC. | $28.41 | 2024 | |
| Exact Sciences Corporation | $22.99 | 2025 | The Cologuard Plus Collection Kit |
| Pfizer INC. | $22.70 | 2024 | |
| Fresenius Kabi USA, LLC | $21.20 | 2023 | Idacio |
| Alnylam Pharmaceuticals INC. | $15.86 | 2025 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Tevlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.